Clinical Trials | August 28, 2023
Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
Global Initiative on Digital Health launched at the G2O Health Minister’s Meeting
The company has new projects in development in Mumbai, Punjab, central and northern India, among others
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
Subscribe To Our Newsletter & Stay Updated
